<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-02-21">21 February 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Andreas</forename><surname>Hochhaus</surname></persName>
							<email>andreas.hochhaus@med.uni-jena.de</email>
							<affiliation key="aff0">
								<orgName type="department">Abteilung Hämatologie/Onkologie</orgName>
								<orgName type="institution" key="instit1">Klinik für Innere Medizin II</orgName>
								<orgName type="institution" key="instit2">Universitätsklinikum Jena</orgName>
								<address>
									<addrLine>Am Klinikum 1</addrLine>
									<postCode>07740</postCode>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Franҫois-Xavier</forename><surname>Mahon</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique</orgName>
								<orgName type="institution">Université Victor Ségalen</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Le Coutre</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ljubomir</forename><surname>Petrov</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Ion Chiricuta Institute of Oncology</orgName>
								<address>
									<settlement>Cluj-Napoca</settlement>
									<country key="RO">Romania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">•</forename><surname>Jeroen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">W M</forename><surname>Janssen</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicholas</forename><forename type="middle">C P</forename><surname>Cross</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">University of Southampton</orgName>
								<address>
									<settlement>Southampton</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Delphine</forename><surname>Rea</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Adult Hematology Department</orgName>
								<orgName type="institution" key="instit1">Hôpital Saint-Louis</orgName>
								<orgName type="institution" key="instit2">APHP</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fausto</forename><surname>Castagnetti</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Experimental, Diagnostic and Specialty Medicine</orgName>
								<orgName type="institution" key="instit1">Institute of Hematology &quot;L. &amp; A. Seràgnoli&quot;, &quot;S Orsola-Malpighi&quot; University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Bologna</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrzej</forename><surname>Hellmann</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Medical University of Gdańsk</orgName>
								<address>
									<settlement>Gdańsk</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gianantonio</forename><surname>Rosti</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Experimental, Diagnostic and Specialty Medicine</orgName>
								<orgName type="institution" key="instit1">Institute of Hematology &quot;L. &amp; A. Seràgnoli&quot;, &quot;S Orsola-Malpighi&quot; University Hospital</orgName>
								<orgName type="institution" key="instit2">University of Bologna</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Norbert</forename><surname>Gattermann</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Hematology, Oncology, and Clinical Immunology</orgName>
								<orgName type="institution">Universitätsklinikum Düsseldorf</orgName>
								<address>
									<settlement>Düsseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>Liz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paciello</forename><surname>Coronel</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">Servicio de Hematología y Hemoterapia</orgName>
								<orgName type="institution" key="instit2">IRYCIS, Hospital Universitario Ramón y Cajal</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>Asuncion</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Echeveste</forename><surname>Gutierrez</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Hospital de Donostia</orgName>
								<address>
									<settlement>San Sebastian</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Valentin</forename><surname>Garcia-Gutierrez</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">Servicio de Hematología y Hemoterapia</orgName>
								<orgName type="institution" key="instit2">IRYCIS, Hospital Universitario Ramón y Cajal</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Beatrice</forename><surname>Vincenzi</surname></persName>
							<affiliation key="aff12">
								<orgName type="laboratory">Novartis Oncology Region Europe</orgName>
								<address>
									<settlement>Origgio</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luca</forename><surname>Dezzani</surname></persName>
							<affiliation key="aff12">
								<orgName type="laboratory">Novartis Oncology Region Europe</orgName>
								<address>
									<settlement>Origgio</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Francis</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
						</author>
						<title level="a" type="main">Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-02-21">21 February 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">EC823B6A3EC2625D72735535F00D8222</idno>
					<idno type="DOI">10.1007/s00432-017-2359-9</idno>
					<note type="submission">Received: 25 January 2017 / Accepted: 27 January 2017 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:25+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>ENEST1st</term>
					<term>Nilotinib</term>
					<term>Chronic myeloid leukemia</term>
					<term>Philadelphia chromosome negative/BCR-ABL positive</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>28 were followed up for molecular assessments.</s><s>At 18 months, the molecular response (MR) 4 rate [MR 4 ; BCR-ABL1 ≤0.01% on International Scale (IS)] was similar in the Ph−/BCR-ABL1+ (39.3%) and Ph+ subgroups (38.1%).</s><s>By 24 months, the cumulative rates of major molecular response (BCR-ABL1 IS ≤0.1%;), MR 4 , and MR 4.5 (BCR-ABL1 IS ≤0.0032%) were 85.7, 60.7, and 50.0%, respectively, in the Ph−/BCR-ABL1 + subgroup, and 80.3, 54.7, and 38.3%, respectively, in the Ph+ subgroup.</s><s>In both Ph−/BCR-ABL1 + and Ph+ subgroups, rash (20 and 22%), pruritus (16.7 and 16.7%), nasopharyngitis (13.3 and 10.4%), fatigue (10 and 14.2%), headache (10 and 15.8%), and nausea (6.7 vs 11.4%) were frequent non-hematologic adverse events, whereas hypophosphatemia (23.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Chronic myeloid leukemia (CML) is characterized by the presence of Philadelphia (Ph) chromosome in &gt;95% of the cases.</s><s>The Ph chromosome, formed as a result of a reciprocal translocation between chromosomes 9 and 22, carries a region that expresses the chimeric BCR-ABL1 gene which encodes for the BCR-ABL1 fusion protein <ref type="bibr" target="#b2">(Bartram et al. 1983;</ref><ref type="bibr" target="#b7">de Klein et al. 1982;</ref><ref type="bibr" target="#b23">Rowley 1973;</ref><ref type="bibr" target="#b27">Shtivelman et al. 1987)</ref>.</s></p><p><s>In very few patients (~5%) with CML, the Ph chromosome is not detectable despite BCR-ABL1 positivity by fluorescent in situ hybridization or reverse transcriptase polymerase chain reaction (RT-PCR).</s><s>The explanation for these cases are that there is a double recombination event involving chromosomes 9 and 22, and in some cases one or more other chromosomes <ref type="bibr" target="#b1">(Bartram 1985;</ref><ref type="bibr" target="#b8">Fitzgerald and Morris 1991;</ref><ref type="bibr" target="#b10">Heim et al. 1985;</ref><ref type="bibr" target="#b17">La Starza et al. 2002;</ref><ref type="bibr">Nishigaki et al. 1992;</ref><ref type="bibr" target="#b25">Seong et al. 1999;</ref><ref type="bibr" target="#b26">Sessarego et al. 2000;</ref><ref type="bibr">Todoric-Zivanovic et al. 2006)</ref>.</s><s>Usually, patients with Phnegative (Ph−)/BCR-ABL1-positive (BCR-ABL1+) CML are clinically not distinguishable from patients with Ph+ CML <ref type="bibr" target="#b0">(Baccarani et al. 2013;</ref><ref type="bibr" target="#b20">Martiat et al. 1991;</ref><ref type="bibr" target="#b25">Seong et al. 1999)</ref>.</s></p><p><s>Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) is approved for the treatment of adult patients with newly diagnosed Ph+ CML in chronic phase (CP) <ref type="bibr" target="#b29">(Tasigna 2015)</ref>.</s><s>In the pivotal phase 3 ENESTnd trial in patients with newly diagnosed CML, nilotinib 300 mg twice daily demonstrated efficacy, with patients achieving early and deep molecular responses and consistent longterm safety profile <ref type="bibr" target="#b12">(Hochhaus et al. 2016b;</ref><ref type="bibr" target="#b16">Kantarjian et al. 2011;</ref><ref type="bibr" target="#b18">Larson et al. 2012;</ref><ref type="bibr" target="#b24">Saglio et al. 2010)</ref>.</s><s>Nilotinib or other TKIs have not been systematically investigated in patients with Ph−/BCR-ABL1 + CML.</s></p><p><s>The ENEST1st study evaluated the safety and efficacy of nilotinib 300 mg twice daily in a large population of patients with newly diagnosed Ph+ or Ph−/BCR-ABL1 + CML-CP.</s><s>In the overall population, the primary endpoint of molecular response (MR) 4 [MR 4 ; BCR-ABL1 ≤0.01% on the International Scale (IS)] at 18 months was achieved by 38.4% of patients <ref type="bibr" target="#b11">(Hochhaus et al. 2016a)</ref>.</s><s>Here, we present data from a sub-analysis of the ENEST1st study based on the Ph status, i.e., Ph+ CML and Ph−/BCR-ABL1 + CML.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design, patients and dosing</head><p><s>The European phase 3b, multicenter, single-arm, open-label ENEST1st trial enrolled adult patients (aged ≥18 years) with newly diagnosed (≤6 months) Ph+ or Ph−/BCR-ABL1 + CML-CP, with molecular confirmation of the BCR-ABL fusion.</s><s>Patients were required to have World Health Organization performance status ≤2.</s><s>Detailed eligibility criteria were previously reported <ref type="bibr" target="#b11">(Hochhaus et al. 2016a)</ref>.</s><s>Patients were treated with nilotinib 300 mg twice daily, and followed for up to 24 months.</s><s>Dose escalation was not permitted, whereas dose interruptions were recommended in patients who experienced study drug-related, clinically significant nonhematologic or noncardiac adverse events (AEs) of grade 2/3 severity, or study drug-related white blood cell-or platelet-related events of grade 3/4 severity.</s></p><p><s>The primary endpoint of the study was the rate of MR 4 at 18 months.</s><s>The secondary endpoints included the rates of major molecular response (MMR; BCR-ABL1 IS ≤0.1%), MR 4 , and MR 4.5 (BCR-ABL1 IS ≤0.0032%) at and by 12 and 24 months of treatment, and safety.</s><s>This subanalysis presents data based on the Ph status at diagnosis <ref type="bibr" target="#b11">(Hochhaus et al. 2016a)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments and definitions</head><p><s>Bone marrow cytogenetic assessments were performed within 8 weeks before the first dose of nilotinib.</s><s>Cytogenetic assessments were performed and analyzed locally using standard methods on at least 20 metaphases; fluorescence in situ hybridization analyses were not used for response assessment.</s><s>Patients with Ph−/BCR-ABL1 + CML and those with unconfirmed Ph status at screening and no Ph+ metaphases at later time points were not assessed for cytogenetic responses.</s></p><p><s>At baseline, the BCR-ABL1 transcript type was determined by multiplex polymerase chain reaction (PCR) <ref type="bibr" target="#b5">(Cross et al. 1994</ref>) and DNA sequencing.</s><s>In subsequent samples, BCR-ABL1 transcripts were quantified every 3 months by quantitative real-time reverse transcriptase qRT-PCR testing of peripheral blood.</s><s>Samples were analyzed at the designated European Treatment and Outcome Study (EUTOS) reference laboratories.</s><s>For each sample, the ratio of BCR-ABL1 transcripts vs control gene (ABL) transcripts converted to IS was calculated <ref type="bibr" target="#b13">(Hughes and Branford 2006;</ref><ref type="bibr" target="#b21">Müller et al. 2008)</ref>.</s></p><p><s>Molecular response was defined according to the definitions of EUTOS <ref type="bibr" target="#b6">(Cross et al. 2012)</ref>.</s></p><p><s>National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 was used for toxicity and adverse event reporting (NCI-CTCAE Version 4.0 2009).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>The subset of patients with major BCR-ABL1 transcripts (i.e., b2a2 and/or b3a2) and ≤3 months of prior imatinib treatment were included in the molecular analysis population.</s><s>Patients with minor BCR-ABL1 transcripts were excluded as the standard qRT-PCR methodology was not optimized for the detection of minor BCR-ABL1 transcripts.</s></p><p><s>The landmark analysis included patients with major BCR-ABL1 transcripts, with no prior imatinib exposure and evaluable qRT-PCR assessments at 3 months.</s><s>Patients who already achieved the target response of MMR, MR 4 , and MR 4.5 at 3 months were excluded from the landmark analysis of MMR, MR 4 , and MR 4.5 , respectively.</s></p><p><s>To calculate response rates "at" a designated time point, patients were considered responders only if an assessment at that time point showed achievement of response.</s><s>Response rates "by" a designated time point were calculated as cumulative response rates, counting all patients with a response detected at or before the specified time point as responders.</s><s>All response rates were calculated as raw proportions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics</head><p><s>This study was conducted in accordance with the International Conference on Harmonization Harmonized Tripartite Guidelines for Good Clinical Practice, the Declaration of Helsinki, and applicable local regulations.</s><s>Informed consent was obtained from all individual participants included in the study.</s><s>The protocol and informed consent forms were reviewed and approved by an institutional review board, independent ethics committee, or research ethics board before the study started at each participating institution.</s><s>ENEST1st was registered in the EU Clinical Trials Registry <ref type="bibr">(2009-017775-19)</ref> and ClinicalTrials.gov</s><s>(NCT01061177).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient disposition and characteristics</head><p><s>The study enrolled 1091 patients from 2010 to 2012 across 307 sites in 26 European countries, and 1089 patients who received ≥1 dose of nilotinib 300 mg twice daily were evaluated.</s><s>Based on cytogenetic assessment, 983 patients were identified as Ph+ and 30 patients were identified as Ph− at screening; 76 patients had unknown karyotype (Fig. <ref type="figure">1</ref>).</s><s>The 30 patients with Ph− status were positive for BCR-ABL1 based on RT-PCR assessment.</s><s>In the Ph− subset, no additional chromosomal aberrations were reported.</s></p><p><s>In the Ph+ subgroup, 952 patients were evaluable for safety and efficacy, and in the Ph−/BCR-ABL1 + subgroup, 28 patients were evaluable for efficacy and all 30 patients were evaluable for safety (Fig. <ref type="figure">1</ref>  <ref type="table" target="#tab_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular response</head><p><s>In total, 28 patients met the criteria for molecular response analysis in the Ph−/BCR-ABL1 + subgroup.</s></p><p><s>The proportion of patients who achieved the primary endpoint of MR 4 at 18 months was similar in both subgroups, with 39.3% (n = 11) in the Ph−/BCR-ABL1 + subgroup and 38.1% (n = 363) in the Ph+ subgroup (Fig. <ref type="figure">2</ref>).</s></p><p><s>In the Ph−/BCR-ABL1 + population, the MR 4 rate was 28.6% at 12 months and 35.7% at 24 months.</s><s>At 12 and 24 months, the respective rates of MMR were 53.6 and 50.0%, and that of MR 4.5 were 17.9 and 7.1% (Fig. <ref type="figure">2</ref>).</s><s>By 12 months, the cumulative rate of MMR was 75.0%,</s><s>MR 4 was 42.9%, and MR 4.5 was 21.4%.</s><s>The cumulative rates of MMR, MR 4 , and MR 4.5 by 24 months were 85.7, 60.7, and 50.0%, respectively (Fig. <ref type="figure">3</ref>).</s><s>In the Ph+ CML population, at 12 and 24 months, the rates of MMR were 55.7 and 61.4%, respectively, MR 4 were 30.7 and 40.4%, respectively, and that of MR 4.5 were 15.3 and 22.5%, respectively (Fig. <ref type="figure">2</ref>).</s><s>The cumulative rates of MMR, MR 4 , and MR 4.5 were 68.3, 36.7, and 20.9% by 12 months, respectively, and 80.3, 54.7, and 38.3% by 24 months, respectively (Fig. <ref type="figure">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Landmark analysis</head><p><s>Of the 14 patients with Ph−/BCR-ABL1 + CML, 12 (85.7%)</s><s>had BCR-ABL1 IS ≤1%, and 1 had BCR-ABL1 IS &gt;1 to ≤10% at 3 months.</s><s>In patients with BCR-ABL1 IS ≤1% at 3 months, the cumulative incidence of MMR was 77.8% (7/9 patients), MR 4 was 58.3% (7/12 patients), and MR 4.5 was 41.7% (5/12 patients) by 24 months.</s></p><p><s>In the Ph+ CML subgroup, the cumulative rates of MMR by 24 months were 88% (300/338 patients), 57.4% (78/136 patients), and 36.4% (8/22 patients) in patients with BCR-ABL1 IS ≤1%, &gt;1 to ≤10%, and &gt;10% at 3 months, respectively.</s><s>The cumulative rates of MR 4 and MR 4.5 by 24 months were 64.8% (333/514 patients) and 46.1% (251/545 patients), respectively, in patients with BCR-ABL1 IS &gt;0% to ≤1% at 3 months, and 24.3% (33/136 patients) and 14% (19/136 patients), respectively, in patients with BCR-ABL1 IS &gt;1 to ≤10% at 3 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>The most frequently reported (≥10%) nonhematological AEs (all grades) included rash (20.0%), pruritus (16.7%), nasopharyngitis (13.3%), diarrhea (10.0%), fatigue (10.0%), arthralgia (10.0%), headache (10.0%), and hypertension (10.0%) in the Ph−/BCR-ABL1 + subgroup, and rash (22.0%), pruritus (16.7%), headache (15.8%), fatigue (14.2%), nausea (11.4%), alopecia (11.0%), and nasopharyngitis (10.4%) in the Ph+ subgroup (Table <ref type="table" target="#tab_2">2</ref>).</s></p><p><s>The most common (≥10%) hematological/biochemical laboratory abnormalities (all grades) were hypophosphatemia (23.3%), alanine aminotransferase increase (ALT, 13.3%), bilirubin increase (13.3%), aspartate aminotransferase increase (AST; 10.0%), lipase increase (10.0%), and anemia (10.0%) in the Ph−/BCR-ABL1 + subgroup, and thrombocytopenia (10.2%) in the Ph+ subgroup (Table <ref type="table" target="#tab_2">2</ref>).</s><s>In patients with Ph−/BCR-ABL1 + CML, two patients (7.1%) experienced grade 3 hypophosphatemia and one patient each (3.6%) experienced dermal cyst, pruritus, urticaria, and ALT increase of grade 3 severity; three patients experienced cardiovascular events, including four grade 3 events.</s><s>Grade 4 anemia occurred in 1 patient (Table <ref type="table" target="#tab_2">2</ref>).</s></p><p><s>In the Ph+ subgroup, thrombocytopenia, lipase increase, neutropenia and hypophosphatemia, anemia, ALT increase, and bilirubin increase of grade 3 severity were experienced by 37 (3.9%), 30 (3.2%), 20 (2.1%), 19 (2%), 17 (1.8%),</s><s>14 (1.5%), and 13 (1.4%)</s><s>patients, respectively.</s><s>Grade 4 thrombocytopenia, neutropenia, and lipase increase were reported in 22 (2.3%), 8 (0.8%), and 7 (0.7%) patients, respectively (Table <ref type="table" target="#tab_2">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The development of BCR-ABL TKIs has revolutionized the therapeutic landscape of CML-CP.</s><s>However, these TKIs have only been approved for the treatment of patients with Ph+ CML <ref type="bibr" target="#b0">(Baccarani et al. 2013;</ref><ref type="bibr" target="#b3">Bisen and Claxton 2013;</ref><ref type="bibr">NCCN 2016)</ref>.</s><s>Sufficient literature is available on the effect of TKIs on patients with Ph+/BCR-ABL1 + CML; however, the effect of TKIs in patients with Ph−/BCR-ABL1 + CML has not been widely explored.</s><s>This report, to the best of our knowledge, is the first of its kind to present data on the effect of nilotinib in patients with Ph−/BCR-ABL1 + CML.</s></p><p><s>In a previous study, the efficacy of interferon-alpha was evaluated in patients with Ph−/BCR-ABL1 + CML in early CP.</s><s>Of the 14 patients who received interferon-alpha, 12 achieved complete hematologic remission, and the median survival duration was 60 months (range 3-&gt;90 months).</s><s>Patients with Ph+ CML and Ph−/BCR-ABL1 + CML were found to have similar characteristics and outcomes <ref type="bibr" target="#b4">(Cortes et al. 1995)</ref>.</s></p><p><s>In the ENEST1st study, among 1052 patients evaluable, the cumulative rates of MMR, MR 4 , and MR 4.5 were 80.4%, 55.2%, and 38.6%, respectively, by 24 months <ref type="bibr" target="#b11">(Hochhaus et al. 2016a)</ref>.</s><s>At 24 months, the estimated  overall survival rate was 98.9% (95% CI, 98.0-99.4%),</s><s>with 13 on study deaths reported, and the estimated rate of freedom from progression to accelerated phase/blast crisis (AP/BC) was 99.4% (95% CI, 98.7-99.7%).</s><s>None of the six patients who progressed to AP/BC on treatment died during study <ref type="bibr" target="#b11">(Hochhaus et al. 2016a)</ref>.</s><s>Results from this study confirm that patients on nilotinib can achieve deep molecular responses, as previously seen in the ENESTnd study <ref type="bibr" target="#b12">(Hochhaus et al. 2016b</ref>).</s></p><p><s>In the current sub-analysis of the ENEST1st trial, the primary endpoint of MR 4 at 18 months was similar between Ph+ (39.3%) and Ph−/BCR-ABL1+ (38.1%) populations.</s><s>The safety profile of nilotinib was also similar between the two populations, with the most frequently reported AEs being hypophosphatemia (23.3%), rash (20.0%), and pruritus (16.7%) in the Ph−/BCR-ABL1 + population, and rash (22.0%), pruritus (16.7%), and headache (15.8%) in the Ph+ population.</s><s>The overall safety results from this study were consistent with the safety profile of nilotinib and similar to that observed in the ENESTnd study <ref type="bibr" target="#b12">(Hochhaus et al. 2016b;</ref><ref type="bibr" target="#b16">Kantarjian et al. 2011;</ref><ref type="bibr" target="#b18">Larson et al. 2012;</ref><ref type="bibr" target="#b24">Saglio et al. 2010;</ref><ref type="bibr" target="#b28">Steegmann et al. 2016)</ref>.</s></p><p><s>Patients with Ph−/BCR-ABL1 + CML and those with unconfirmed Ph status at screening and no Ph+ metaphases at later time points were not eligible for cytogenetic response analysis.</s><s>Of the 983 patients evaluable, complete cytogenetic response rate was 67.3% (n = 662; 95% CI, 64.4-70.3%)</s><s>by 6 months and 82.5% (n = 811; 95% CI, 80.1-84.9%)</s><s>by 12 months <ref type="bibr" target="#b11">(Hochhaus et al. 2016a</ref>).</s><s>In the overall population in the ENEST1st study, 97% of the patients achieved BCR-ABL1 IS ≤10% at 3 months (Hochhaus et al. 2016a), a molecular target which is recommended for the achievement of better long-term outcomes <ref type="bibr" target="#b0">(Baccarani et al. 2013;</ref><ref type="bibr">NCCN 2016)</ref>, as seen in prior studies <ref type="bibr" target="#b9">(Hanfstein et al. 2012;</ref><ref type="bibr" target="#b14">Hughes et al. 2014;</ref><ref type="bibr" target="#b15">Jabbour et al. 2014;</ref><ref type="bibr" target="#b19">Marin et al. 2012)</ref>.</s><s>Based on the landmark analysis, greater proportion of patients with BCR-ABL1 IS ≤1% at 3 months vs BCR-ABL1 IS &gt;1% at 3 months achieved MR 4 (65.0 vs 24.1%) and MR 4.5 (45.8 vs 14.5%) by 24 months <ref type="bibr" target="#b11">(Hochhaus et al. 2016a</ref>).</s><s>However, this conclusion cannot be drawn in Ph−/BCR-ABL1 + patients due to lower patient count.</s><s>In total, 12 of the 14 patients evaluable had BCR-ABL1 IS ≤1% at 3 months, and only one patient had BCR-ABL1 IS &gt;1% at 3 months; by 24 months, 58 and 41.7% of the patients with BCR-ABL1 IS ≤1% at 3 months achieved MR 4 and MR 4.5 , respectively.</s></p><p><s>The study was not designed to compare the two patient populations; also due to huge disparity between the numbers in each group, any meaningful comparisons cannot be drawn.</s></p><p><s>In conclusion, baseline characteristics, risk scores, and MR rates were found to be similar between the Ph−/BCR-ABL1 + and Ph+ subgroups, and nilotinib is active in this previously unexplored population.</s><s>Adverse events observed in Ph−/BCR-ABL1 + CML patients were also found to be similar to the ones observed in the Ph+ CML patients.</s><s>In the background of similar molecular response and safety profiles seen in patients with Ph−/BCR-ABL1 + CML when compared with the Ph+ CML population, this rare population subgroup benefits from nilotinib treatment in the same way as Ph+ patients.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig</head><label></label><figDesc><div><p><s>Fig. 1 Patient disposition</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 Fig. 3</head><label>23</label><figDesc><div><p><s>Fig. 2 Molecular responses during treatment at different time points in Ph-/BCR-ABL1 + CML (n = 28) (a) and Ph+ CML (n = 952) (b).</s><s>MMR major molecular response (BCR-ABL1 IS ≤ 0.1%), MR molecular response, MR 4 MR with 4-log reduction in BCR-ABL transcript (BCR-ABL1 IS ≤ 0.01%), MR 4.5 MR with 4.5-log reduction in BCR-ABL transcript (BCR-ABL1 IS ≤ 0.0032%)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline characteristics and demographics</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>Ph−/BCR-ABL1 + CML</cell><cell>Ph+ CML (n = 983)</cell></row><row><cell></cell><cell>(n = 30)</cell><cell></cell></row><row><cell>Age, median (range), years</cell><cell>51.5 (21.0-75.0)</cell><cell>53.0 (18.0-91.0)</cell></row><row><cell>Sex (Male/Female), n (%)</cell><cell>17 (56.7)/13 (43.3)</cell><cell>581 (59.1)/402 (40.9)</cell></row><row><cell>Race, n (%)</cell><cell></cell><cell></cell></row><row><cell>Caucasian</cell><cell>30 (100)</cell><cell>941 (95.7)</cell></row><row><cell>Prior therapies a,b n (%)</cell><cell></cell><cell></cell></row><row><cell>None</cell><cell>5 (16.7)</cell><cell>301 (30.6)</cell></row><row><cell>Imatinib ≤1 month</cell><cell>2 (6.7)</cell><cell>59 (6.0)</cell></row><row><cell>Imatinib &gt;1-2 months</cell><cell>3 (10.0)</cell><cell>62 (6.3)</cell></row><row><cell>Imatinib &gt;2 months</cell><cell>10 (33.3)</cell><cell>35 (3.6)</cell></row><row><cell>Hydroxyurea</cell><cell>10 (33.3)</cell><cell>524 (53.3)</cell></row><row><cell>Type of BCR-ABL transcripts, n (%)</cell><cell></cell><cell></cell></row><row><cell>b3a2</cell><cell>16 (53.3)</cell><cell>482 (49.0)</cell></row><row><cell>b2a2</cell><cell>10 (33.3)</cell><cell>362 (36.8)</cell></row><row><cell>b3a2 and b2a2</cell><cell>3 (10.0)</cell><cell>111 (11.3)</cell></row><row><cell>Not assessed at baseline</cell><cell>1 (3.3)</cell><cell>3 (0.3)</cell></row><row><cell>Sokal score, median (range)</cell><cell>0.87 (0.51-8.92)</cell><cell>0.86 (0.44-5.55)</cell></row><row><cell>High risk, n (%)</cell><cell>7 (23.3)</cell><cell>178 (18.1)</cell></row><row><cell>Intermediate risk, n (%)</cell><cell>9 (30.0)</cell><cell>366 (37.2)</cell></row><row><cell>Low risk, n (%)</cell><cell>10 (33.3)</cell><cell>342 (34.8)</cell></row><row><cell>Missing, n (%)</cell><cell>4 (13.3)</cell><cell>97 (9.9)</cell></row><row><cell>EUTOS score, median (range)</cell><cell>0.39 (0-0.94)</cell><cell>0.34 (0-3)</cell></row><row><cell>High risk, n (%)</cell><cell>2 (6.7)</cell><cell>90 (9.2)</cell></row><row><cell>Low risk, n (%)</cell><cell>26 (86.7)</cell><cell>806 (82.0)</cell></row><row><cell>Missing, n (%)</cell><cell>2 (6.7)</cell><cell>87 (8.9)</cell></row></table><note><p><s>a Patients who received imatinib and hydroxyurea and/or other drugs are counted within the imatinib categories only.</s><s>Patients who received hydroxyurea plus other drugs (not imatinib) are counted within the hydroxyurea category only b Two additional patients in the Ph+ subgroup received therapies other than imatinib and/or hydroxyurea: one patient received cytarabine for 7 days, and other patient received capecitabine and oxaliplatin</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>Adverse events and</cell></row><row><cell>laboratory abnormalities</cell></row><row><cell>occurring in ≥ 10% of patients</cell></row><row><cell>at any grade or ≥ 1% of patients</cell></row><row><cell>at grade 3/4 in the Ph−/BCR-</cell></row><row><cell>ABL1 + CML or Ph+ CML</cell></row><row><cell>subgroups</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="14">Division of Hematology Oncology, Developmental Therapeutics Program, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank all physicians, study coordinators and documentation assistants for their active participation and cooperation.</s><s>In addition to the authors of this report, members of the Scientific Study Management Committee included Philippe Rousselot, MD and David Marin, MD and members of the data management committee included Nelson Spector, MD, PhD and Armand Keating, MD, FRCP.</s><s>We also thank Vijay Kadasi, MSc, Novartis Healthcare Pvt Ltd for medical editorial assistance with this manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with ethical standards</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>The study was sponsored by Novartis Pharmaceuticals.</s></p><p><s>Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/),</s><s>which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">European LeukemiaNet recommendations for the management of chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2013-05-501569</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="872" to="884" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bartram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="2175" to="2179" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bartram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">306</biblScope>
			<biblScope unit="page" from="277" to="280" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Claxton</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-1-4614-6176-0_8</idno>
	</analytic>
	<monogr>
		<title level="j">Adv Exp Med Biol</title>
		<imprint>
			<biblScope unit="volume">779</biblScope>
			<biblScope unit="page" from="179" to="196" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Talpaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Beran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Rios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="464" to="470" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Melo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="186" to="189" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Standardized definitions of molecular response in chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2012.104</idno>
		<idno>doi:10.1038/ leu.2012.104</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2172" to="2175" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Klein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">300</biblScope>
			<biblScope unit="page" from="765" to="767" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement?</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Morris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Genet Cytogenet</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="143" to="151" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hanfstein</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2012.85</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2096" to="2102" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Variant Ph translocations in chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Heim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Billstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kristoffersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mandahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Strombeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mitelman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Genet Cytogenet</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="215" to="227" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2015.270</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="57" to="64" />
			<date type="published" when="2016">2016a</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2016.5</idno>
		<imprint>
			<date type="published" when="2016">2016b</date>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1044" to="1054" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Branford</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.blre.2005.01.008</idno>
	</analytic>
	<monogr>
		<title level="j">Blood Rev</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="29" to="41" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2013-06-510396</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="1353" to="1360" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Jabbour</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2013-06-511592</idno>
		<idno>doi:10.1182/ blood-2013-06-511592</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="494" to="500" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1470-2045(11)70201-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="841" to="851" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">La</forename><surname>Starza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="143" to="147" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2012.134</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2197" to="2203" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Marin</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2011.38.6565</idno>
		<idno>doi:10.1200/ jco.2011.38.6565</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="232" to="238" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Philadelphia-negative (Ph−) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique</title>
		<author>
			<persName><forename type="first">P</forename><surname>Martiat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Michaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodhain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="205" to="211" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.leu.2404983</idno>
		<idno>doi:10.1038/ sj.leu.2404983</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="96" to="102" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">National Comprehensive Cancer Network, Fort Washington NCI-CTCAE (Version 4.0 2009) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. National Cancer Institute: Bethesda Nishigaki H</title>
	</analytic>
	<monogr>
		<title level="m">Absence in Phnegative. M-BCR rearrangement-positive chronic myelogenous leukemia of linkage between 5′ ABL 3′ M-BCR sequences in Philadelphia translocation</title>
				<meeting><address><addrLine>Misawa S, Inazawa J, Abe</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1992">2016. 1992</date>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="385" to="392" />
		</imprint>
	</monogr>
	<note>NCCN</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Rowley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">243</biblScope>
			<biblScope unit="page" from="290" to="293" />
			<date type="published" when="1973">1973</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0912614</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="2251" to="2259" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization</title>
		<author>
			<persName><forename type="first">D</forename><surname>Seong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="955" to="959" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sessarego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fugazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bruzzone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ballestrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miglino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bacigalupo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="35" to="39" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">bcr-abl RNA in patients with chronic myelogenous leukemia</title>
		<author>
			<persName><forename type="first">E</forename><surname>Shtivelman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="971" to="973" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Steegmann</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2016.104</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1648" to="1671" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
		<author>
			<persName><surname>Tasigna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tasigna</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>package insert</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1)</title>
		<idno type="DOI">10.1016/j.cancergencyto.2005.11.008</idno>
	</analytic>
	<monogr>
		<title level="j">Novartis Pharmaceuticals Corporation</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="180" to="185" />
			<date type="published" when="2006">2006</date>
		</imprint>
		<respStmt>
			<orgName>East Hanover Todoric-Zivanovic B et al</orgName>
		</respStmt>
	</monogr>
	<note>Cancer Genet Cytogenet</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
